These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 4612283)

  • 1. [Clinical and biological study of a new vascular protective agent and hypolipemic agent, pyridoxine para-chloro-phénoxy-isobutyrate. (Claresan)].
    Fourrier A; Mouton Y
    Lille Med; 1974 Apr; 19(4 Suppl 11):532-7. PubMed ID: 4612283
    [No Abstract]   [Full Text] [Related]  

  • 2. [Pyridoxine para-chloro-phenoxy-isobutyrate. Analysis of hypolipidemic effects].
    Mirouze J; Orsetti A; Cartry E
    Nouv Presse Med; 1973 Dec; 2(46):3115-6. PubMed ID: 4787779
    [No Abstract]   [Full Text] [Related]  

  • 3. [Clinical experimentation of clofibride. Apropos of 40 cases].
    Warembourg H; Jaillard J
    Lille Med; 1973 Dec; 18(10 Suppl 5):suppl 5:1292-6. PubMed ID: 4802928
    [No Abstract]   [Full Text] [Related]  

  • 4. [Effect of a new synthetic compound (3-nicotinoyl-oxypropyl p-chlorophenoxy isobutyrate: I.612) on plasma lipids in patients with type IIa, IIb and IV hyperdyslipidemia].
    Bucalossi A; Buzzelli G; D'Alessandro A
    Clin Ter; 1979 Apr; 89(2):127-49. PubMed ID: 226307
    [No Abstract]   [Full Text] [Related]  

  • 5. Atilipidemic drugs. Part 5: Evaluation of the hypolipidemic effect of LF 178 in 191 patients affected by the atherogenic form of endogenous hyperlipoproteinemia (types IIa, IIb and IV).
    Rouffy J; Dreux C; Goussault Y; Dakkak R; Renson FJ
    Arzneimittelforschung; 1976; 26(5):901-6. PubMed ID: 183788
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical research into the hypolipemic and platelet antiaggregant activity of plafibride, Carried out in double-blind conditions and in comparison with clofibrate.
    Palmieri B; Gasparini Casari M; DiBlasio P; Zirilli E
    Arzneimittelforschung; 1981; 31(10a):1863-6. PubMed ID: 7032534
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gemfibrozil and clofibrate in the treatment of hyperlipidaemias. A comparative trial.
    Eisalo A; Manninen V
    Proc R Soc Med; 1976; 69 Suppl 2(Suppl 2):44-6. PubMed ID: 798196
    [No Abstract]   [Full Text] [Related]  

  • 8. [Clinical trial of tibric acid, a new hypolipidemic agent].
    Noseda G; Sirtori CR
    Schweiz Med Wochenschr; 1974 Dec; 104(51):1917-22. PubMed ID: 4438990
    [No Abstract]   [Full Text] [Related]  

  • 9. [Comparative studies on the cholesterol and triglyceride-lowering effect of alpha-methylthyroxine (Skleronorm) and clofibrate (Regelan) in hyperlipoproteinemias of type IIa/b and IV].
    Jantke J; Schwartzkopff W; Zschiedrich M
    Verh Dtsch Ges Inn Med; 1977 Apr 17-21; 83():392-5. PubMed ID: 206057
    [No Abstract]   [Full Text] [Related]  

  • 10. A clofibrate controlled trial of gemfibrozil in the treatment of hyperlipidaemias.
    Tuomilehto J; Salonen J; Kuuisto P; Virtamo J; Manninen V; Mälkönen M
    Proc R Soc Med; 1976; 69 Suppl 2(Suppl 2):38-40. PubMed ID: 798195
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Therapeutic trial of a normolipemic agent: ethanolamine N-oxy-nicotinate].
    Warembourg H; Ketelers JY; Ginestet A
    Lille Med; 1973 Dec; 18(10 Suppl 5):suppl 5:1331-5. PubMed ID: 4608970
    [No Abstract]   [Full Text] [Related]  

  • 12. [Bis-(hydroxy-2-ethylthyo)-1,10-decano in hyperlipaemic therapy (author's transl)].
    Cucinotta D; Palummeri E; Ceccato S; Passeri M
    G Ital Cardiol; 1977; 7(3):248-64. PubMed ID: 858465
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Clinical trials with Fonlipol. Apropos of 50 cases].
    Warembourg H; Jaillard J
    Lille Med; 1974 Apr; 19(4 Suppl 11):528-31. PubMed ID: 4612282
    [No Abstract]   [Full Text] [Related]  

  • 14. Does hypolipidemic therapy prevent coronary heart disease?
    Rifkind BM; Levy RI
    Cardiovasc Clin; 1974; 6(2):1-8. PubMed ID: 4374303
    [No Abstract]   [Full Text] [Related]  

  • 15. [New drug combination for medical management of hyperlipemia: clinical study].
    Fischer M; Falkensammer C
    Int J Clin Pharmacol Biopharm; 1977 Dec; 15(12):585-9. PubMed ID: 340391
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [The management of hyperlipoproteinemia with Liproreduct].
    Fenster R
    Ther Ggw; 1974 May; 113(5):813-24. PubMed ID: 4603893
    [No Abstract]   [Full Text] [Related]  

  • 17. [Hypolipemic effects of 1-10(hydroxy-2 ethylthio) decane (LL1558), based on 77 cases of essential hyperlipidemia].
    Rouffy J; Loeper J
    Therapie; 1972; 27(3):433-44. PubMed ID: 4570211
    [No Abstract]   [Full Text] [Related]  

  • 18. The efficacy of lipid lowering drugs alone and in combination.
    Hansen PF
    Postgrad Med J; 1975; 51(8):63-5. PubMed ID: 768949
    [No Abstract]   [Full Text] [Related]  

  • 19. [Drug therapy of dyslipidemias].
    Lenzi S
    Minerva Med; 1975 Oct; 66(66):3479-82. PubMed ID: 1178140
    [No Abstract]   [Full Text] [Related]  

  • 20. [Clinical study of thiadenol in diabetic hyperdyslipemia as compared with clofibrate].
    Nicrosini F; Pasotti C
    Clin Ter; 1979 Aug; 90(3):241-50. PubMed ID: 553752
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.